SCHEMBL23112013

SCHEMBL23112013

NC(=O)c1ccc(OCc2c(C(=O)O)sc3cccc(F)c23)cc1

nearest known ligand 0.61

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
STING1 Q86WV6 15/20 0.61
PARP10 Q53GL7 5/20 0.52
MAOB P27338 3/20 0.52
PARP15 Q460N3 1/20 0.52
PARP14 Q460N5 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23111951 0.88 STING1 (0.52) STING1PARP10MAOBPARP15PARP14
SCHEMBL23112081 0.87 PARP10 (0.52) STING1PARP10MAOBPARP15PARP14
SCHEMBL23635899 0.86 STING1 (0.70) STING1PARP10MAOBPARP15PARP14
SCHEMBL23630796 0.86 STING1 (0.55) STING1PARP10MAOBPARP15PARP14
SCHEMBL23111974 0.86 STING1 (0.68) STING1PARP10
SCHEMBL23630771 0.86 STING1 (0.53) STING1PARP10MAOBPARP15PARP14
SCHEMBL30313238 0.86 ALDH1A1 (0.59) STING1PARP10MAOBPARP15PARP14
SCHEMBL23635796 0.86 ALDH1A1 (0.59) STING1PARP10MAOBPARP15PARP14
SCHEMBL23111996 0.86 STING1 (0.64) STING1
SCHEMBL23630786 0.85 STING1 (0.53) STING1PARP10MAOBPARP15PARP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092009-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING CTXT PTY LTD (AU) 2025-03-20 US disclosed
CN-112424181-B Substituted condensed thiophenes as STING modulators 希泰克斯特私人有限公司 2024-02-27 CN disclosed
EP-3793988-B1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING CTXT PTY LTD (AU) 2023-11-15 EP disclosed
EP-3793988-B1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING CTXT PTY LTD (AU) 2023-11-15 EP disclosed
US-20230227423-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING CTXT PTY LTD (AU) 2023-07-20 US disclosed
US-20230227423-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING CTXT PTY LTD (AU) 2023-07-20 US disclosed
US-20230227423-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING CTXT PTY LTD (AU) 2023-07-20 US disclosed
US-11613525-B2 Substituted condensed thiophenes as modulators of sting CTXT PTY LIMITED (AU) 2023-03-28 US disclosed
US-20210214333-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING CTXT PTY LTD. (AU) 2021-07-15 US disclosed
US-20210214333-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING CTXT PTY LTD. (AU) 2021-07-15 US disclosed
EP-3793988-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING Ctxt Pty Ltd (AU) 2021-03-24 EP disclosed
CN-112424181-A Substituted condensed thiophenes as STING modulators 希泰克斯特私人有限公司 2021-02-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227423-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING STING1, CGAS, IRF3 STING1 1/4885PARP10 2170/4885MAOB 390/4885
US-20210214333-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING STING1, CGAS, IRF3 STING1 1/4885PARP10 2493/4885MAOB 334/4885
US-11613525-B2 Substituted condensed thiophenes as modulators of sting STING1, CGAS, IRF3 STING1 1/4885PARP10 2493/4885MAOB 334/4885
US-20250092009-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING STING1, CGAS, IRF3 STING1 1/4885PARP10 2170/4885MAOB 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.